Mixed Results For China’s First Home-Grown COVID Antiviral

Russia Trial Meets Endpoints

 
• By Dexter Jie Yan

A preliminary analysis of Russian Phase III results for azvudine, China's first home-grown antiviral for COVID-19, shows it reached two primary endpoints, but a separate Chinese study produced mixed results.

azvudine trial results
Genuine Biotech needs to submit complete Phase III data for azvudine within three years of conditional approval • Source: Shutterstock

More from China

More from Focus On Asia